Literature DB >> 31853688

A new clinical respiratory distress score for surfactant therapy in preterm infants with respiratory distress.

Debasish Nanda1, Sushma Nangia2, Anu Thukral3, C P Yadav4.   

Abstract

The guidelines for surfactant therapy are largely based on studies done in developed coun1tries wherein the facility infrastructure, patient profile, and clinical practices are different from low- and middle-income countries (LMICs). Though SRT is widely practiced in developing countries, there exists variability in clinical practice. Our objective was to identify the factors which would predict the need of surfactant administration and develop a "clinical respiratory distress (RD) score" for surfactant administration in preterm neonates with respiratory distress. A prospective observational study was conducted in 153 preterm infants (260/7 to 346/7 weeks gestation) with respiratory distress who were managed with CPAP and/or surfactant where indicated. Gestation < 32 weeks, no antenatal corticosteroid (ANS), hypothermia at admission, Apgar score < 3 at 1 minute, and Silverman score > 2 at 2 hours were found to be the significant factors in predicting surfactant requirement in multivariate regression analysis. A seven point scale was developed and categorized into two categories as < 4 and ≥ 4. The sensitivity, specificity, PPV, and NPV were 67%, 87%, 86%, and 68%, respectively, with a cutoff score ≥ 4. The positive likelihood ratio was 5.07 (95% CI 2.71-9.48), and negative likelihood ratio was 0.38 (95% CI 0.28-0.52). The observed rate of surfactant administration was found to be around 32% when the composite score was below four, and the rate increased to almost 86% when the composite score was ≥ 4. The predictive accuracy of the model was subsequently evaluated in a cohort of 56 preterm infants with respiratory distress.. Sensitivity, specificity and positive and negative predictive value during the validation phase were 97%, 73%, 85%, and 94%, respectively. With a composite score less than 4, the observed rate of surfactant administration was 6% (95% CI 1%-28%) as against the model predicted rate of 24%, while with composite score ≥ 4, the observed rate was 85% (95% CI 69%-94%) as against the model predicted rate of 90%.
Conclusion: "Clinical RD score" is a simple score, which can be utilized for decision-making for early surfactant administration for preterm infants (260/7 to 346/7 weeks gestation) with respiratory distress.Trial Registration: NCT03273764What is Known:• Both CPAP and surfactant therapy are effective in management of preterm infants with RDS.• The efficacy of surfactant replacement therapy is better when it is administered early in the course of disease.What is New:• Many of the known risk factors for RDS do not predict surfactant requirement.• "Composite RD score" comprising of five independent predictors of surfactant requirement with a numeric cutoff may help decide which preterm neonates with respiratory distress need early surfactant administration in low- and middle-income countries.

Entities:  

Keywords:  Antenatal steroids; CPAP; Preterm infants; RD score; RDS; Surfactant

Year:  2019        PMID: 31853688     DOI: 10.1007/s00431-019-03530-5

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  23 in total

1.  Surfactant therapy for hyaline membrane disease: the Chandigarh experience.

Authors:  A Narang; P Kumar; S Dutta; R Kumar
Journal:  Indian Pediatr       Date:  2001-06       Impact factor: 1.411

2.  A controlled clinical trial of effects of water mist on obstructive respiratory signs, death rate and necropsy findings among premature infants.

Authors:  W A SILVERMAN; D H ANDERSEN
Journal:  Pediatrics       Date:  1956-01       Impact factor: 7.124

3.  Prophylactic or early selective surfactant combined with nCPAP in very preterm infants.

Authors:  Fabrizio Sandri; Richard Plavka; Gina Ancora; Umberto Simeoni; Zbynek Stranak; Stefano Martinelli; Fabio Mosca; José Nona; Merran Thomson; Henrik Verder; Laura Fabbri; Henry Halliday
Journal:  Pediatrics       Date:  2010-05-03       Impact factor: 7.124

4.  Early routine versus late selective surfactant in preterm neonates with respiratory distress syndrome on nasal continuous positive airway pressure: a randomized controlled trial.

Authors:  Hemasree Kandraju; Srinivas Murki; Sreeram Subramanian; Pramod Gaddam; Ashok Deorari; Praveen Kumar
Journal:  Neonatology       Date:  2012-12-11       Impact factor: 4.035

5.  New Ballard Score, expanded to include extremely premature infants.

Authors:  J L Ballard; J C Khoury; K Wedig; L Wang; B L Eilers-Walsman; R Lipp
Journal:  J Pediatr       Date:  1991-09       Impact factor: 4.406

Review 6.  Early surfactant administration with brief ventilation vs. selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome.

Authors:  T P Stevens; E W Harrington; M Blennow; R F Soll
Journal:  Cochrane Database Syst Rev       Date:  2007-10-17

7.  Nasal continuous positive airway pressure and early surfactant therapy for respiratory distress syndrome in newborns of less than 30 weeks' gestation.

Authors:  H Verder; P Albertsen; F Ebbesen; G Greisen; B Robertson; A Bertelsen; L Agertoft; B Djernes; E Nathan; J Reinholdt
Journal:  Pediatrics       Date:  1999-02       Impact factor: 7.124

8.  Very early surfactant without mandatory ventilation in premature infants treated with early continuous positive airway pressure: a randomized, controlled trial.

Authors:  Mario Augusto Rojas; Juan Manuel Lozano; Maria Ximena Rojas; Matthew Laughon; Carl Lewis Bose; Martin Alonso Rondon; Laura Charry; Jaime Alberto Bastidas; Luis Alfonso Perez; Catherine Rojas; Oscar Ovalle; Luz Astrid Celis; Jorge Garcia-Harker; Martha Lucia Jaramillo
Journal:  Pediatrics       Date:  2009-01       Impact factor: 7.124

9.  Early CPAP versus surfactant in extremely preterm infants.

Authors:  Neil N Finer; Waldemar A Carlo; Michele C Walsh; Wade Rich; Marie G Gantz; Abbot R Laptook; Bradley A Yoder; Roger G Faix; Abhik Das; W Kenneth Poole; Edward F Donovan; Nancy S Newman; Namasivayam Ambalavanan; Ivan D Frantz; Susie Buchter; Pablo J Sánchez; Kathleen A Kennedy; Nirupama Laroia; Brenda B Poindexter; C Michael Cotten; Krisa P Van Meurs; Shahnaz Duara; Vivek Narendran; Beena G Sood; T Michael O'Shea; Edward F Bell; Vineet Bhandari; Kristi L Watterberg; Rosemary D Higgins
Journal:  N Engl J Med       Date:  2010-05-16       Impact factor: 91.245

Review 10.  Efficacy and safety of CPAP in low- and middle-income countries.

Authors:  A Thukral; M J Sankar; A Chandrasekaran; R Agarwal; V K Paul
Journal:  J Perinatol       Date:  2016-05       Impact factor: 2.521

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.